Ayala Pharmaceuticals (NASDAQ:ADXS) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXSFree Report) in a report released on Saturday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

NASDAQ ADXS opened at $0.60 on Friday. The stock’s 50 day simple moving average is $0.73 and its 200 day simple moving average is $0.80. Ayala Pharmaceuticals has a one year low of $0.51 and a one year high of $1.95.

About Ayala Pharmaceuticals

(Get Free Report)

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.

Further Reading

Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.